Eosinophilic fasciitis induced by nivolumab therapy managed without treatment interruption or systemic immunosuppression
JAAD Case Reports(2020)
摘要
Initially described by Shulman in 1974, eosinophilic fasciitis (EF) is a rare fibrosing disorder involving the fascia.1 Patients with EF are often treated with systemic glucocorticoids as a first-line treatment.1 The pathogenesis is unclear; immunophenotyping studies have found involvement of immune-mediated mechanisms involving macrophages and CD8+ T lymphocytes.2 There are increasing reports of cutaneous immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs) in cancer therapy.
更多查看译文
关键词
autoimmunity,checkpoint inhibition,cutaneous toxicities,eosinophilic fasciitis,immune checkpoint inhibitors,immune-related adverse event,PD-1/L1 inhibition
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要